Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye

11Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its use in postvitrectomy eyes has not been reported. We present a case of an 89-year-old female, with recurrent choroidal neovascularization 10 years following prior macular translocation vitrectomy surgery for neovascular age-related macular degeneration, successfully treated with monthly aflibercept injections initiated following poor response to a single initial bevacizumab injection. This report suggests that aflibercept may be an important treatment option for vitrectomized eyes requiring anti-VEGF treatment.

Cite

CITATION STYLE

APA

Hahn, P. (2014). Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye. Clinical Ophthalmology, 8, 2129–2131. https://doi.org/10.2147/OPTH.S73265

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free